Creating the standard for neuropsychiatry
with best-in-class real-world evidence
Neuropsychiatry needs better evidence to drive decision-making. There is currently no standardized way to measure symptoms or quality of care for neuropsychiatric conditions, making innovation in the field difficult to achieve.
We know that real-world data and analytics can revolutionize the neuropsychiatry landscape by unlocking new and much-needed evidence to guide decisions for successful treatment development, efficient care delivery, and improved patient outcomes.
That's why we've built the field's largest, most robust source of clinical data for real-world data and a uniquely powerful evidence engine. We're ready to set the standard for neuropsychiatry.
GET STARTED
Real-World Evidence for
Real-World impact
Gold-standard data, elevated evidence
We have captured and mapped de-identified data from patient electronic health records across the U.S. to create NeuroBlu Data, a single source of truth that reflects how neuropsychiatry care is delivered. This data powers NeuroBlu Analytics, Holmusk's evidence engine that enables researchers to build patient cohorts, conduct studies at an unprecedented level of granularity, and generate impactful evidence.
Patients
State coverage
Years of longitudinal data
Longitudinal
Follow patients over time with over 20 years of data, spanning inpatient and outpatient sites, including hospitals, emergency rooms, and community psychiatry clinics.
Fit-for-purpose
Conduct observational studies with data that are curated and ready to address your most challenging research questions.
Comprehensive
Track patient functioning and outcomes and compare different groups of patients with standardized quantitative outcome measures.
Enriched data for deeper clinical context
NeuroBlu Data is enriched through the application of natural language processing models—the first to be developed specifically for neuropsychiatry.
These models extract important information from unstructured clinical notes within the electronic health record and transform it into standardized measures, adding valuable context to research by making more fit-for-purpose data available than ever before.
Holmusk offers a range of digital solutions aimed at harnessing real-world data to improve neuropsychiatry. Whether you're a researcher, a clinician, or a payer, we have a data-driven solution for your challenges.
NeuroBlu: Impactful insights powered by real-world data
Analytics software
Access insights in just a few clicks with our user-friendly data analytics software, complete with no-code analytics capabilities and pre-designed study templates so you can get the answers you need faster.
Clinical expertise
Conduct analysis within NeuroBlu Analytics alongside our team of clinical and data science experts, who will guide you through the design and execution of an end-to-end study tailored specifically to your organization's needs.
Information on a wide variety of conditions, such as:
•Substance use disorders: 255k+ patients
•Major depressive disorder: 251k+ patients
•Bipolar disorder: 134k+ patients
•Attention-deficit/hyperactivity disorder: 82k+ patients
•Post-traumatic stress disorder: 63k+ patients
•Schizoaffective disorder: 34k+ patients
•Schizophrenia: 33k+ patients
•Borderline personality disorder: 19k+ patients
•Autism spectrum disorder: 16k+ patients
Access to behavioral health assessments, enabling researchers to study disease severity and outcomes. These assessments include:
•Substance use disorders: 255k+ patients
•Major depressive disorder: 251k+ patients
•Bipolar disorder: 134k+ patients
•Attention-deficit/hyperactivity disorder: 82k+ patients
•Post-traumatic stress disorder: 63k+ patients
•Schizoaffective disorder: 34k+ patients
•Schizophrenia: 33k+ patients
•Borderline personality disorder: 19k+ patients
•Autism spectrum disorder: 16k+ patients
Access to rich data on pharmacological treatments, giving researchers the ability to determine effectiveness of treatments for patient subsegments, and identify trends to inform precision psychiatry. These treatments include:
•Substance use disorders: 255k+ patients
•Major depressive disorder: 251k+ patients
•Bipolar disorder: 134k+ patients
•Attention-deficit/hyperactivity disorder: 82k+ patients
•Post-traumatic stress disorder: 63k+ patients
•Schizoaffective disorder: 34k+ patients
•Schizophrenia: 33k+ patients
•Borderline personality disorder: 19k+ patients
•Autism spectrum disorder: 16k+ patients
Digital solutions to better leverage real-world data
Make informed, data-driven decisions with our Management and Supervision Tool (MaST), a clinical decision support tool used in the U.K. that leverages data visualization and predictive analytics to prioritize individuals at risk of crisis and improve caseload management.
Information on a wide variety of conditions, such as:
•Substance use disorders: 255k+ patients
•Major depressive disorder: 251k+ patients
•Bipolar disorder: 134k+ patients
•Attention-deficit/hyperactivity disorder: 82k+ patients
•Post-traumatic stress disorder: 63k+ patients
•Schizoaffective disorder: 34k+ patients
•Schizophrenia: 33k+ patients
•Borderline personality disorder: 19k+ patients
•Autism spectrum disorder: 16k+ patients
Access to behavioral health assessments, enabling researchers to study disease severity and outcomes. These assessments include:
•Substance use disorders: 255k+ patients
•Major depressive disorder: 251k+ patients
•Bipolar disorder: 134k+ patients
•Attention-deficit/hyperactivity disorder: 82k+ patients
•Post-traumatic stress disorder: 63k+ patients
•Schizoaffective disorder: 34k+ patients
•Schizophrenia: 33k+ patients
•Borderline personality disorder: 19k+ patients
•Autism spectrum disorder: 16k+ patients
Access to rich data on pharmacological treatments, giving researchers the ability to determine effectiveness of treatments for patient subsegments, and identify trends to inform precision psychiatry. These treatments include:
•Substance use disorders: 255k+ patients
•Major depressive disorder: 251k+ patients
•Bipolar disorder: 134k+ patients
•Attention-deficit/hyperactivity disorder: 82k+ patients
•Post-traumatic stress disorder: 63k+ patients
•Schizoaffective disorder: 34k+ patients
•Schizophrenia: 33k+ patients
•Borderline personality disorder: 19k+ patients
•Autism spectrum disorder: 16k+ patients
LEARN MORE
Real-World Evidence for
Real-World impact
Collaborating across the neuropsychiatry ecosystem
Our solutions have been leveraged by a range of stakeholders who share our vision that better evidence can vastly improve neuropsychiatry.
R&D for drug development
- Optimize trial design by leveraging data on symptoms and outcomes (e.g. CGI-S) to identify patients in the real world who meet study criteria
- Validate design assumptions by tracking real-world outcomes of patient cohorts
- Identify additional diagnoses as potential new targets for existing drugs
Medical affairs
- Characterize disease burden of specific sub-cohorts of neuropsychiatry patients
- Generate evidence to illustrate existing gaps in treatment and how new drugs of interest help bridge these gaps
- Identify patients best suited for newly approved or launched drugs
Market access and health economics & outcomes research
- Obtain advanced characterization of factors that may inhibit success, such as predictors of poor outcomes, lack of tolerability, and adherence to treatment
- Understand optimal positioning of new products or lifecycle management of existing products to inform communication to payers and health care providers
- Identify patient segments that are eligible for new drugs and use real-world outcomes to inform formulary decision-making
Payers and value-based care
- Monitor behavioral health utilization to optimize management strategies and understand patient journeys
- Track and analyze patient outcomes over time and assess the effectiveness of different treatments and interventions
- Identify high-risk patients with predictive analytics for early interventions
Holmusk has been recognized for innovation in behavioral health by:
See How We Collaborate
Follow the latest evolutions in real-world evidence
Publications
Explore recent peer-reviewed publications and conference abstracts that leverage NeuroBlu Data to share new real-world evidence with the scientific community.
Read More
News
Catch up on the latest company announcements, including news about novel collaborations, innovative projects, awards, and more.
Read More
Thought leadership
Curious about the latest developments in real-world evidence and neuropsychiatry? Check out our blog, the Hol Picture, where leaders from across Holmusk share thoughts.
Read More
We’d love for you to come along on the journey of improving neuropsychiatry with better evidence.
Curious about what’s happening in the real-world evidence space? Check out our blog, the Hol Picture, where we share takeaways from recent talks and weigh in on news involving real-world evidence and behavioral health.
Publications
Explore recent peer-reviewed publications and conference abstracts that leveraged NeuroBlu data to share new real-world evidence with the scientific community.
Read More
News
Catch up on the latest company announcements, including news about novel collaborations, innovative projects, awards, and more.
Read More
Thought Leadership
Curious about the latest developments in real-world evidence and mental health? Check out our blog, the Hol Picture, where leaders from across Holmusk share thoughts.
Read More
We’re making fast strides toward a reimagined future for behavioral health, and we’d love for you to come along on our journey.